Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of istradefylline for end-of-dose wearing-off in Parkinson's disease treated with levodopa
CTR20230645Phase 3Terminated
- Sponsor
- Shandong Innovation Drug R&D
- Start
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Istradefylline in Parkinson's disease (PD), sponsored by Shandong Innovation Drug R&D. Started Jun 2023; status: terminated.
02
Drugs
Istradefylline
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on CTR20230645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230645.